Individualized Treatment Effect Estimation

Estimating heterogeneous treatment effects with machine learning has attracted substantial attention in both academic research and industrial practice. However, the two communities often evaluate models under markedly different conditions. Methodological work typically relies on semi-simulated benchmarks and metrics that require counterfactual outcomes, whereas real-world applications rely on observable metrics based on ranking or test outcomes. Despite the well-known gap between methodological progress and practical deployment, the relationship between these evaluation regimes has not been examined systematically. We conduct a large-scale empirical study of treatment effect evaluation across standard semi-simulated benchmark families and real-world datasets. Our benchmark covers meta-learners paired with multiple base learners, as well as specialized causal machine learning models. We evaluate these methods using observable metrics common in application-oriented literature, alongside counterfactual metrics commonly used in methods papers. Our results reveal two complementary gaps. First, counterfactual metrics do not reliably recover the estimators preferred by observable metrics, even on the same semi-simulated benchmarks. Second, rankings obtained on semi-simulated benchmarks do not transfer to real datasets. We further find that simple meta-learners with strong base models are consistently competitive, in contrast to specialized causal models. Overall, our findings suggest that progress in treatment effect estimation research should not be assessed solely through counterfactual metrics and semi-simulated benchmarks, but it would benefit from incorporating observable metrics and real-data validation.

Individual treatment effects are not point-identified from data. The Probability of Necessity and Sufficiency (PNS) circumvents this limitation by characterizing individual-level causality through intersection bounds derived from combined experimental and observational data. In finite samples, however, standard plug-in estimators systematically fail: they violate structural probability constraints and suffer from extremum bias induced by max-min operators, yielding spuriously narrow intervals. We propose a neural framework for finite-sample PNS estimation that resolves both pathologies. We introduce an anchored neural architecture that guarantees structural constraint satisfaction by construction. To correct extremum bias, we employ precision-corrected intersection-bound inference, leveraging Epistemic Neural Networks for scalable, high-dimensional uncertainty quantification. Empirical evaluations confirm that this approach maintains nominal coverage and exact constraint validity in high-dimensional regimes where standard estimators systematically undercover.

Estimating individualized treatment effects from longitudinal observational data is central to data-driven medicine, yet existing methods face a fundamental limitation: reducing confounding bias often suppresses clinically informative heterogeneity, degrading patient-specific predictions. Here, we identify this tension as a bias-precision paradox in causal representation learning and introduce sampling-based maximum mean discrepancy (sMMD), a stochastic alignment strategy that replaces global adversarial balancing with subset-level matching. We instantiate this approach in a framework for counterfactual outcome prediction with attribution-grounded interpretability. Across two large-scale ICU cohorts (n = 27,783), our framework improves accuracy under distribution shift, reducing error by up to 11.5% and substantially increasing recall in high-risk tasks. Mechanistic analyses show that sMMD selectively preserves clinically decisive variables. In human-AI evaluation, our method outperforms clinicians-in-training and large language models, and improves clinician accuracy by 14.7% while reducing decision time, enabling interpretable, real-time clinical decision support.

Conditional Average Treatment Effect (CATE) estimation in practice demands three properties simultaneously: heterogeneous effects $τ(x)$, calibrated uncertainty over them, and robustness to the heavy tails that contaminate real outcome data. Meta-learners (Künzel et al., 2019) give (i); causal forests and BART give (i)-(ii) with Gaussian-tail assumptions; no widely used tool gives all three. We present Bayesian X-Learner, an X-Learner built on cross-fitted doubly robust pseudo-outcomes (Kennedy, 2020) with a full MCMC posterior over $τ(x)$ via a Welsch redescending pseudo-likelihood. On Hill's IHDP benchmark the default configuration attains mean $\sqrt{\varepsilon_{\mathrm{PEHE}}} = 0.56$ on 5 replications (lowest mean; differences from S-/T-/X-learners, full-config Causal BART, and a causal forest baseline are not significant at $α=0.05$, and rank ordering is unstable at 10 replications -- IHDP comparisons are competitive rather than dominant). On contaminated "whale" DGPs with up to 20-25% tail density, a one-flag extension (contamination_severity) that selects a Huber-$δ$ nuisance loss per Huber's minimax-$δ$ relation recovers RMSE $\approx 0.13$ with tight credible intervals (single-cross-fit 30-seed coverage 83% [Wilson 66%, 93%] at 20% density; modular-Bayes pooling with Bayesian-bootstrap nuisance draws restores nominal 95% coverage).

Randomized controlled trials often do not represent the populations where decisions are made, and covariate shift across studies can invalidate standard IPD meta-analysis and transport estimators. We propose a placebo-anchored transport framework that treats source-trial outcomes as abundant proxy signals and target-trial placebo outcomes as scarce, high-fidelity gold labels to calibrate baseline risk. A low-complexity (sparse) correction anchors proxy outcome models to the target population, and the anchored models are embedded in a cross-fitted doubly robust learner, yielding a Neyman-orthogonal, target-site doubly robust estimator for patient-level heterogeneous treatment effects when target treated outcomes are available. We distinguish two regimes: in connected targets (with a treated arm), the method yields target-identified effect estimates; in disconnected targets (placebo-only), it reduces to a principled screen--then--transport procedure under explicit working-model transport assumptions. Experiments on synthetic data and a semi-synthetic IHDP benchmark evaluate pointwise CATE accuracy, ATE error, ranking quality for targeting, decision-theoretic policy regret, and calibration. Across connected settings, the proposed method is best or near-best and improves substantially over proxy-only, target-only, and transport baselines at small target sample sizes; in disconnected settings, it retains strong ranking performance for targeting while pointwise accuracy depends on the strength of the working transport condition.

Precision mental health requires treatment decisions that account for heterogeneous symptoms reflecting multiple clinical domains. However, existing methods for estimating individualized treatment effects (ITE) rely on a single summary outcome or a specific set of observed symptoms or measures, which are sensitive to symptom selection and limit generalizability to unmeasured yet clinically relevant domains. We propose DRIFT, a new maximin framework for estimating robust ITEs from high-dimensional item-level data by leveraging latent factor representations and adversarial learning. DRIFT learns latent constructs via generalized factor analysis, then constructs an anchored on-target uncertainty set that extrapolates beyond the observed measures to approximate the broader hyper-population of potential outcomes. By optimizing worst-case performance over this uncertainty set, DRIFT yields ITEs that are robust to underrepresented or unmeasured domains. We further show that DRIFT is invariant to admissible reparameterizations of the latent factors and admits a closed-form maximin solution, with theoretical guarantees for identification and convergence. In analyses of a randomized controlled trial for major depressive disorder (EMBARC), DRIFT demonstrates superior performance and improved generalizability to external multi-domain outcomes, including side effects and self-reported symptoms not used during training.

In personalized marketing, uplift models estimate the incremental effect of an intervention by modeling how customer behavior would change under alternative treatments using counterfactual analysis. However, real-world marketing data often exhibit various biases, such as selection bias, spillover effects, measurement error, and unobserved confounding. These biases can adversely affect both the accuracy of uplift estimation and the validity of evaluation metrics. Despite the importance of bias-aware assessment, there remains a lack of systematic studies evaluating how different models and metrics perform under such biased conditions. To bridge this gap, we design a systematic benchmarking framework. Unlike standard predictive tasks, real-world uplift datasets inherently lack counterfactual ground truth. This limitation renders the direct validation of evaluation metrics infeasible and prevents the precise quantification of biases. Therefore, a semi-synthetic approach serves as a critical enabler for systematic benchmarking. This approach effectively bridges the gap by retaining real-world feature dependencies while providing the ground truth needed to isolate structural biases. Our investigations reveal that (i) uplift targeting and prediction can manifest as distinct objectives, where proficiency in one does not ensure efficacy in the other; (ii) while many models exhibit inconsistent performance under diverse biases, TARNet shows notable robustness, providing insights for subsequent model design; (iii) the stability of evaluation metrics is linked to their mathematical alignment with the ATE, suggesting that ATE-approximating metrics yield more consistent model rankings under structural data imperfections. These findings suggest the need for more robust uplift models and evaluation metrics under real-world data imperfections.

Randomized controlled trials (RCTs) are the gold standard for estimating treatment effects, yet they are often underpowered for detecting effect heterogeneity. Large observational studies (OS) can supplement RCTs for conditional average treatment effect (CATE) estimation, but a key barrier is covariate mismatch: the two sources measure different, only partially overlapping, covariates. We propose CALM (Calibrated ALignment under covariate Mismatch), which learns embeddings that map each source's features into a common representation space. OS outcome models are transferred to the RCT embedding space and calibrated using trial data, preserving causal identification from randomization. Finite-sample risk bounds decompose into alignment error, outcome-model complexity, and calibration complexity terms, making explicit when the learned embedding is accurate enough to reduce variance. We instantiate CALM in two forms: a closed-form linear version, CALM-Lin, and a neural representation-learning version, CALM-NN. Across 51 simulation settings, calibration-based linear methods are effectively tied in linear-CATE regimes, while CALM-NN wins all 22 nonlinear-CATE settings by wide margins. Moreover, on two real-data studies CALM-NN delivers the largest gains over the trial-only baseline.

Estimating Individual Treatment Effects (ITE) in multi-treatment scenarios faces two critical challenges: the Hyperparameter Selection Dilemma for balancing weights and the Curse of Dimensionality in computational scalability. This paper derives a novel multi-treatment generalization bound and proposes a theoretical estimator for the optimal balancing weight $α$, eliminating expensive heuristic tuning. We investigate three balancing strategies: Pairwise, One-vs-All (OVA), and Treatment Aggregation. While OVA achieves superior precision in low-dimensional settings, our proposed Treatment Aggregation ensures both accuracy and O(1) scalability as the treatment space expands. Furthermore, we extend our framework to a generative architecture, Multi-Treatment CausalEGM, which preserves the Wasserstein geodesic structure of the treatment manifold. Experiments on semi-synthetic and image datasets demonstrate that our approach significantly outperforms traditional models in estimation accuracy and efficiency, particularly in large-scale intervention scenarios.

Estimating heterogeneous treatment effects (HTEs) from right-censored survival data is critical in high-stakes applications such as precision medicine and individualized policy-making. Yet, the survival analysis setting poses unique challenges for HTE estimation due to censoring, unobserved counterfactuals, and complex identification assumptions. Despite recent advances, from Causal Survival Forests to survival meta-learners and outcome imputation approaches, evaluation practices remain fragmented and inconsistent. We introduce SurvHTE-Bench, the first comprehensive benchmark for HTE estimation with censored outcomes. The benchmark spans (i) a modular suite of synthetic datasets with known ground truth, systematically varying causal assumptions and survival dynamics, (ii) semi-synthetic datasets that pair real-world covariates with simulated treatments and outcomes, and (iii) real-world datasets from a twin study (with known ground truth) and from an HIV clinical trial. Across synthetic, semi-synthetic, and real-world settings, we provide the first rigorous comparison of survival HTE methods under diverse conditions and realistic assumption violations. SurvHTE-Bench establishes a foundation for fair, reproducible, and extensible evaluation of causal survival methods. The data and code of our benchmark are available at: https://github.com/Shahriarnz14/SurvHTE-Bench .

Precision medicine promises to transform health care by offering individualised treatments that dramatically improve clinical outcomes. A necessary prerequisite is to identify subgroups of patients who respond differently to different therapies. Current approaches are limited to static measures of treatment success, neglecting the repeated measures found in most clinical trials. Our approach combines the concept of partly conditional modelling with treatment effect estimation based on the Virtual Twins method. The resulting time-specific responses to treatment are characterised using survLIME, an extension of Local Interpretable Model-agnostic Explanations (LIME) to survival data. Performance was evaluated using synthetic data and applied to clinical trials examining the effectiveness of panitumumab to treat metastatic colorectal cancer. An area under the receiver operating characteristic curve (AUC) of 0.77 for identifying fixed responders was achieved in a 1000 patient simulation. When considering dynamic responders, partly conditional modelling increased the AUC from 0.597 to 0.685. Applying the approach to colorectal cancer trials found genetic mutations, sites of metastasis, and ethnicity as important factors for response to treatment. Our approach can accommodate a dynamic response to treatment while potentially providing better performance than existing methods in instances of a fixed response to treatment. When applied to clinical data we attain results consistent with the literature.

Heterogeneous treatment effects (HTEs) are increasingly estimated using machine learning models that produce highly personalized predictions of treatment effects. In practice, however, predicted treatment effects are rarely interpreted, reported, or audited at the individual level but, instead, are often aggregated to broader subgroups, such as demographic segments, risk strata, or markets. We show that such aggregation can induce systematic bias of the group-level causal effect: even when models for predicting the individual-level conditional average treatment effect (CATE) are correctly specified and trained on data from randomized experiments, aggregating the predicted CATEs up to the group level does not, in general, recover the corresponding group average treatment effect (GATE). We develop a unified statistical framework to detect and mitigate this form of group bias in randomized experiments. We first define group bias as the discrepancy between the model-implied and experimentally identified GATEs, derive an asymptotically normal estimator, and then provide a simple-to-implement statistical test. For mitigation, we propose a shrinkage-based bias-correction, and show that the theoretically optimal and empirically feasible solutions have closed-form expressions. The framework is fully general, imposes minimal assumptions, and only requires computing sample moments. We analyze the economic implications of mitigating detected group bias for profit-maximizing personalized targeting, thereby characterizing when bias correction alters targeting decisions and profits, and the trade-offs involved. Applications to large-scale experimental data at major digital platforms validate our theoretical results and demonstrate empirical performance.

We study the problem of selecting the best heterogeneous treatment effect (HTE) estimator from a collection of candidates in settings where the treatment effect is fundamentally unobserved. We cast estimator selection as a multiple testing problem and introduce a ground-truth-free procedure based on a cross-fitted, exponentially weighted test statistic. A key component of our method is a two-way sample splitting scheme that decouples nuisance estimation from weight learning and ensures the stability required for valid inference. Leveraging a stability-based central limit theorem, we establish asymptotic familywise error rate control under mild regularity conditions. Empirically, our procedure provides reliable error control while substantially reducing false selections compared with commonly used methods across ACIC 2016, IHDP, and Twins benchmarks, demonstrating that our method is feasible and powerful even without ground-truth treatment effects.

We propose a generalization of the synthetic control methods to the setting with dynamic treatment effects, in which each unit receives multiple treatments sequentially, according to an adaptive policy that depends on a latent, endogenously time-varying confounding state. Under a low-rank latent factor model assumption, which admits linear time-varying and time-invariant dynamic triangular systems as special cases, we develop an identification strategy for any unit-specific mean outcome under any sequence of interventions. Our method, which we term synthetic blips, is a backward induction process in which the blip effect of a treatment at each period for a target unit is recursively expressed as a linear combination of the blip effects of other units that received the designated treatment, avoiding the combinatorial donor requirements of naive synthetic control extensions. We provide easy-to-implement estimation algorithms that yield consistent estimators. Using unique Korean firm-level panel data, we estimate individualized dynamic treatment effects and optimal allocation rules in the context of financial support for exporting firms.